Authors
Bingqian Cao, Li Zhou, Shouzhang Hu, Yue Huang
Published in
Frontiers in microbiology. Volume 17. Pages 1948754. Epub Oct 06, 2026.
Abstract
The low-FODMAP diet is recommended by clinical guidelines as an effective dietary strategy for alleviating symptoms in patients with irritable bowel syndrome (IBS). However, its effect on Bifidobacterium and Faecalibacterium prausnitzii (F. prausnitzii) remains unclear, largely due to methodological heterogeneity.
We systematically searched the literature up to September 2026 for randomized controlled trials comparing low-FODMAP diets with control diets in adults with IBS. Given the high methodological heterogeneity across studies, we performed a direction-of-effect and consistency analysis (vote counting and sign test) instead of a traditional meta-analysis.
12 RCTs were included. For Bifidobacterium (11 studies), 9 (81.8%) reported a decrease and 2 reported no change; the sign test confirmed a consistent reduction (p = 0.033). A sensitivity analysis including only studies with direct between-group comparisons (9 studies) was consistent with the aforementioned analysis (8 reported a decrease, p = 0.020). For F. prausnitzii (7 studies), the evidence was inconsistent: 2 reported a decrease, 4 reported no change, and 1 reported an increase, with no statistically significant trend.
Most current evidence indicates that a low FODMAP diet reduces the abundance of Bifidobacterium in IBS patients, while its effect on F. prausnitzii remains unclear. This finding enables clinicians to conduct more evidence-based counseling with patients, clarifying the specific effects (and non-effects) of the low-FODMAP diet on microbiota and facilitating informed decision-making regarding dietary management. Furthermore, future research should investigate the dynamics of microbiota during the reintroduction phase and consider patient microbiota subtypes to clarify the overall impact of the diet on the microbiota.
This systematic review has been registered with PROSPERO (International Prospective Register of Systematic Reviews) under the registration number CRD420261351146. The publicly accessible URL is: https://www.crd.york.ac.uk/PROSPERO/.
PMID:
42903081
Bibliographic data and abstract were imported from PubMed on 22 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0